According to sources, the health ministry of the United Arab Emirates has said that an experimental COVID-19 vaccine produced by Sinopharm, a Chinese state-owned pharmaceutical company, has shown 86 percent efficacy in trials held in the United Arab Emirates(UAE).
The ministry said that the analysis shows, “99 percent seroconversion rate of neutralizing antibody and 100 percent effectiveness in preventing moderate and severe cases of the disease and no serious safety concerns.”
The vaccine uses an inactivated virus unable to replicate human cells to trigger immune responses and requires two doses to be effective. Phase 3 of the clinical trials started way back in July in the UAE.
The vaccine may be late in the results of its clinical trials but it is to be noted that the candidate vaccine was already granted the Emergency Use Authorization (EUA) to protect frontline workers from the virus. It is estimated that around 1 million people have already received the vaccine under this authorization.
The trials were conducted in the UAE with 31,000 volunteers from 125 different nationalities taking part in the trials. The UAE trial is a partnership between Sinopharm, Abu Dhabi-based artificial intelligence company Group 42 (G42), and the Abu Dhabi Department of Health.
Image Source: CNBC
The Federal Board of Revenue (FBR) has introduced a comprehensive mechanism for blocking and unblocking…
Bitcoin broke the $100,000 mark for the first time on Thursday, driven by Trump's crypto-friendly…
On Thursday, the Pakistan Stock Exchange (PSX) 100 Index surged by 1,781.94 points, or 1.86%,…
Shaza Fatima Khawaja, Minister of State for IT and Telecom, made it clear on Thursday…
PayPal, the global payment processing company, announced on Friday that it had successfully resolved a…
LAHORE: Punjab government colleges have completed the recruitment of 7,354 teaching interns. The Higher Education…